Prescient Therapeutics (ASX:PTX) has extended the closing date of its share purchase plan (SPP) to Sept. 15 from Sept. 8, giving eligible shareholders more time to participate in the AU$7 million capital raising following delays in receiving documentation, according to a Tuesday filing with the Australian bourse.
Eligible shareholders can apply under the SPP for up to AU$30,000 worth of new shares at AU$0.065 each, per the filing.
The funds will be used to support the advancement of PTX-100 beyond the Dose Optimization Committee meeting, expected in December, and to guide the study's continuation and further development, the filing added.